Search

Search Constraints

You searched for: Author/Creator Garralda, E.

Search Results

1. 157P Phase I expansion of IMC-C103C, a MAGE-A4×CD3 ImmTAC bispecific protein, in ovarian carcinoma. (December 2022)

2. 173P First-in-human study to evaluate the safety and clinical activity of FS222: A tetravalent bispecific antibody targeting PD-L1 and CD137, in patients with advanced solid tumors. (December 2022)

3. 201P Phase II study of taminadenant (A2AR antagonist) + spartalizumab (anti PD-1 antibody) in patients with triple-negative breast cancer (TNBC). (December 2022)

4. 304 Vanucizumab reduces vessel permeability, perfusion and cellular density of tumor lesions in cancer patients as measured by DCE-MRI and DW-MRI. (September 2015)

5. 335 Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors. (September 2015)

7. Dose escalation study of OMO-103, a first in class Pan-MYC-Inhibitor in patients (pts) with advanced solid tumors. (October 2022)

8. Integrated palliative care in Europe: a qualitative systematic literature review of empirically-tested models in cancer and chronic disease. Issue 1 (December 2016)

9. Non-invasive biomarkers for response and survival prediction in patients with advanced solid tumours treated with immune checkpoint inhibitors (ICIs). (October 2022)

10. Representation of young adult(19–29 y) and elderly(>75 y) patients populations in an early drug development unit. (October 2022)